237 related articles for article (PubMed ID: 15351620)
21. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization.
Okamura T; Umemoto Y; Yasui T; Saiki S; Kuroda H; Kotoh S; Kamizaki H
Int J Clin Oncol; 2004 Oct; 9(5):373-7. PubMed ID: 15549587
[TBL] [Abstract][Full Text] [Related]
23. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
24. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
25. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
Rauser S; Weis R; Braselmann H; Feith M; Stein HJ; Langer R; Hutzler P; Hausmann M; Lassmann S; Siewert JR; Höfler H; Werner M; Walch A
Clin Cancer Res; 2007 Sep; 13(17):5115-23. PubMed ID: 17785566
[TBL] [Abstract][Full Text] [Related]
26. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
27. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
[TBL] [Abstract][Full Text] [Related]
28. Fluorescence in situ hybridization study of chromosome abnormalities of upper urinary tract urothelial carcinoma in paraffin-embedded tissue.
Bing Z; Li J; Master SR; Lee CC; Puthiyaveettil R; Tomaszewski JE
Am J Clin Pathol; 2012 Sep; 138(3):382-9. PubMed ID: 22912355
[TBL] [Abstract][Full Text] [Related]
29. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder.
Krüger S; Mess F; Böhle A; Feller AC
Int J Oncol; 2003 Jul; 23(1):41-8. PubMed ID: 12792774
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
31. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine.
Dalquen P; Kleiber B; Grilli B; Herzog M; Bubendorf L; Oberholzer M
Cancer; 2002 Dec; 96(6):374-9. PubMed ID: 12478686
[TBL] [Abstract][Full Text] [Related]
32. Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes.
Zitzelsberger H; Szücs S; Weier HU; Lehmann L; Braselmann H; Enders S; Schilling A; Breul J; Höfler H; Bauchinger M
J Pathol; 1994 Apr; 172(4):325-35. PubMed ID: 8207613
[TBL] [Abstract][Full Text] [Related]
33. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer.
Nguyen CT; Litt DB; Dolar SE; Ulchaker JC; Jones JS; Brainard JA
Urology; 2009 Feb; 73(2):347-50. PubMed ID: 19022486
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
36. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
[TBL] [Abstract][Full Text] [Related]
37. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma.
Luo B; Li W; Deng CH; Zheng FF; Sun XZ; Wang DH; Dai YP
Cancer Genet Cytogenet; 2009 Mar; 189(2):93-7. PubMed ID: 19215789
[TBL] [Abstract][Full Text] [Related]
38. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization.
Mendelin J; Grayson M; Wallis T; Visscher DW
Lab Invest; 1999 Apr; 79(4):387-93. PubMed ID: 10211991
[TBL] [Abstract][Full Text] [Related]
39. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
[TBL] [Abstract][Full Text] [Related]
40. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
